Suppr超能文献

弥漫性大B细胞淋巴瘤的发展意外地为一名难治性经典霍奇金淋巴瘤患者带来了挽救生命的治疗。

Development of Diffuse Large B-cell Lymphoma Serendipitously Led to Life-Saving Treatment in a Patient with Refractory Classical Hodgkin Lymphoma.

作者信息

Mori Minako, Sakai Tomomi, Oka Tomomi, Moriyoshi Koki, Kawabata Hiroshi

机构信息

Department of Hematology, NHO Kyoto Medical Center, Japan.

Department of Diagnostic Pathology, NHO Kyoto Medical Center, Japan.

出版信息

Intern Med. 2025 May 1;64(9):1399-1403. doi: 10.2169/internalmedicine.4334-24. Epub 2024 Sep 18.

Abstract

A 65-year-old man with generalized lymphadenopathy was diagnosed with classical Hodgkin lymphoma-mixed cellularity via left cervical lymph node biopsy. Initial treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine led to complete metabolic remission (CMR); however, recurrence developed after 6 months. Brentuximab vedotin induced partial remission followed by systemic relapse after 10 months. Nivolumab led to a second CMR, but disease progression persisted over nearly 4 years, despite treatment adjustments and local radiotherapy. Eventually, the patient was diagnosed with diffuse large B-cell lymphoma during routine esophagogastroduodenoscopy. Four courses of rituximab-CHOP therapy led to a CMR. This case highlights the importance of performing re-biopsies to detect the recurrence or progression of lymphoma.

摘要

一名65岁的男性,伴有全身淋巴结肿大,经左颈淋巴结活检被诊断为经典型霍奇金淋巴瘤-混合细胞型。初始使用阿霉素、博来霉素、长春花碱和达卡巴嗪治疗后达到完全代谢缓解(CMR);然而,6个月后复发。使用维布妥昔单抗诱导部分缓解,10个月后出现全身复发。纳武单抗导致第二次CMR,但尽管进行了治疗调整和局部放疗,疾病进展仍持续了近4年。最终,患者在常规食管胃十二指肠镜检查期间被诊断为弥漫性大B细胞淋巴瘤。四个疗程的利妥昔单抗-CHOP治疗导致CMR。该病例强调了再次活检以检测淋巴瘤复发或进展的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1555/12120223/202cb9d9ec30/1349-7235-64-1399-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验